+91 80 2808 2808

Biocon Ranked Among Top 5 Biotech Employers Globally

  • Posted by: BIOCON

Bengaluru, Karnataka, India, October 30, 2020

Biocon Ltd, an innovation-led global biopharmaceuticals company, has ranked among the Top 5 Global Biotech Employers for 2020 on the prestigious U.S.-based Science magazine’s annual ‘Science Careers Top 20 Employers’ list. Ranked at No. 5 among global pharma and biotech companies in 2020, Biocon has moved up steadily from No. 7 in 2018 and No. 6 in 2019. The company has consistently featured among the top global employers for eight consecutive years, since its debut on the list in 2012.

According to the Top Employers Survey of approximately 7,600 respondents from across the world this year, Biocon’s ranking was based on three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees’.

This year, the survey took place from March 3 through May 3, when companies globally were grappling with quarantines and lockdowns in response to COVID-19. In these extraordinary circumstances, Biocon reinforced its reputation of resilience and reliability by continuing to manufacture and supply life-saving therapies worldwide while prioritizing the health and safety of its employees through comprehensive safety measures at its facilities.

Biocon Executive Chairperson Kiran Mazumdar-Shaw said, “We are delighted to be ranked among the Top Five Global Biotech Employers by Science Magazine. The ranking is a recognition of the passion that our employees bring to the job, which allowed us to run essential and critical manufacturing, quality and supply operations with reduced staffing despite the severe disruptions caused by the COVID-19 outbreak, thus minimizing the impact on patients and partners. Their commitment also enabled us to rapidly develop novel therapeutics for the deadly coronavirus and serve humanity by fighting COVID-19.”

“We will continue to build on Biocon’s employee-friendly culture that promotes ideation, experimentation and collaboration as we aspire to create future leaders who will revolutionize healthcare through innovative products and services,” she added.

The Top 5 global players in this year’s list are Regeneron, Alnylam, Incyte, Syngenta and Biocon.

Biocon was ahead of leading global pharma companies like Novo Nordisk, Roche, Eli Lilly, Abbott, Novartis, Pfizer etc. in the 2020 rankings.

Top 10 Employers for 2020

2020 Rank 2019 Rank Employer (Global HQ)
1 2 Regeneron (Tarrytown, NY)
2 3 Incyte (Wilmington, DE)
3 1 Alnylam Pharmaceuticals (Cambridge, MA)
4 10 Syngenta (Basel, Switzerland)
5 6 Biocon Limited (Bangalore, India)
6 4 Merck KGaA (Darmstadt, Germany)
7 20 Novo Nordisk (Bagsværd, Denmark)
8 12 Vertex Pharmaceuticals (Boston, MA)
9 11 Moderna (Cambridge, MA)
10 5 Spark Therapeutics (Philadelphia, PA)

For the companies that emerged in the top 20, remarks from respondents reflected their pride and gratitude in the fact that the organizations they represented had continuously invested in their well-being while still putting science and patients first. When employees see meaningful action by their employers that is designed to empower and support them in every way possible, they respond in kind: They produce their best work. And in the arena of pharma and biotech, that easily translates into better patient outcomes, The American Association for the Advancement of Science (AAAS) said.

DNA of Top Employers: The winning formulation that puts companies on the Top Employers list? Chief among the ingredients is an articulated mission of supporting scientists and science. Almost all of the top employers indicated that they are science- and patient-centered, AAAS added.

Read More:

About Biocon Ltd:

Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as generic formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Follow-us on Twitter: @bioconlimited

Biocon Biologics Limited, a subsidiary of Biocon Limited, is uniquely positioned as a fully integrated ‘pure play’ biosimilars organization in the world. Building on the four pillars of Patients, People, Partners and Business, Biocon Biologics is committed to transforming healthcare and transforming lives. Biocon Biologics is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower treatment costs while improving healthcare outcomes. It has a platform of 28 biosimilar molecules across diabetes, oncology, immunology, dermatology, ophthalmology, neurology, rheumatology and inflammatory diseases. Five molecules from Biocon Biologics’ portfolio have been taken from lab to market, of which three have been commercialized in developed markets like United States, EU, Australia, Canada and Japan. It aspires to benefit 5 million patient lives with its biosimilars and attain a revenue milestone of USD 1 billion in FY22. Follow-us on Twitter:  @BioconBiologics

About AAAS:

The American Association for the Advancement of Science (AAAS) is the world’s largest general scientific society and publisher of the journal Science, as well as Science Translational Medicine; Science Signaling; a digital, open-access journal, Science Advances; Science Immunology; and Science Robotics. AAAS was founded in 1848 and includes nearly 250 affiliated societies and academies of science, serving 10 million individuals. Science has the largest paid circulation of any peer-reviewed general science journal in the world. The nonprofit AAAS is open to all and fulfills its mission to “advance science and serve society” through initiatives in science policy, international programs, science education, public engagement, and more. For additional information about AAAS, see

Author: BIOCON
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>